Next 10 |
home / stock / chsyf / chsyf news
SHENZHEN, CHINA, April 23, 2024 (GLOBE NEWSWIRE) -- Desidustat Tablets are novel, oral HIF-PHI for treating anaemia in non-dialysis adult chronic kidney disease patients. The Product is administrated orally, thus expecting to improve the treatment compliance of patients and to meet the unme...
2024-04-07 06:30:00 ET Summary ProfoundBio, a Seattle ADC company with an R&D facility in Suzhou, will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. China Medical System in-licensed povorcitinib, an oral JAK1 inhibitor, from San Franciscoȁ...
Povorcitinib, a selective oral JAK1 inhibitor discovered by Incyte, is an investigational medicine being evaluated for the treatment of non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria HONG KONG, China and WILMINGTON, De...
2024-03-28 08:38:29 ET More on China Medical System Holdings Limited Historical earnings data for China Medical System Holdings Limited Financial information for China Medical System Holdings Limited Read the full article on Seeking Alpha For further details ...
SHENZHEN, CHINA, March 27, 2024 (GLOBE NEWSWIRE) -- On March 27, 2024, China Medical System (“CMS” or the “Company”) released its 2023 annual results. The Company recorded a turnover of RMB8,013 million, a year-on-year decrease of 12.4%; in the case that all medicines ...
2024-02-11 01:25:00 ET Summary I-Mab Hangzhou will acquire rights to I-Mab’s drug assets in Greater China for $80 M. Anbogen Therapeutics raised $12.5M in a Series A funding round. to advance its two lead drug candidates. Bayer signed a non-binding Letter of Intent to m...
SHENZHEN, CHINA, Feb. 03, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 2 February 2024, the Group through its wholly-owned subsidiary entered into a Novation Agreement (the “Novation Agreeme...
SHENZHEN, CHINA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- On 29 December, 2023, PharmaGend Global Medical Services Pte. Ltd. (“PharmaGend”), jointly invested by China Medical System Holdings Limited (“CMS”), through its wholly-owned subsidiary CMS MEDICAL VENTURE PTE. LTD., a...
SHENZHEN, CHINA, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Innovative drugs VALTOCO (Diazepam Nasal Spray),ILUMETRI (Tildrakizumab Injection) and rare disease drug Tetrabenazine Tablets have been newly included in China’s National Reimbursement Drug List(NRDL), XinHuoSu (Recombinant H...
SHENZHEN, CHINA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- The New Drug Application for an additional rheumatoid arthritis (RA) indication of Methotrexate Injection has been accepted by NMPA, which is a new milestone following the China approval for psoriasis indication of Methotrexate Injection. T...
News, Short Squeeze, Breakout and More Instantly...
China Medical Sys Hldgs Company Name:
CHSYF Stock Symbol:
OTCMKTS Market:
SHENZHEN, CHINA, April 23, 2024 (GLOBE NEWSWIRE) -- Desidustat Tablets are novel, oral HIF-PHI for treating anaemia in non-dialysis adult chronic kidney disease patients. The Product is administrated orally, thus expecting to improve the treatment compliance of patients and to meet the unme...
Povorcitinib, a selective oral JAK1 inhibitor discovered by Incyte, is an investigational medicine being evaluated for the treatment of non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria HONG KONG, China and WILMINGTON, De...
SHENZHEN, CHINA, March 27, 2024 (GLOBE NEWSWIRE) -- On March 27, 2024, China Medical System (“CMS” or the “Company”) released its 2023 annual results. The Company recorded a turnover of RMB8,013 million, a year-on-year decrease of 12.4%; in the case that all medicines ...